skip to main content

Recurrent uncomplicated lower urinary tract infection in a postmenopausal woman receiving adjuvant aromatase-i

Instant feedback + full explanation. One question, done properly.

HardUrinary Tract InfectionsRecurrent uncomplicated lower urinary tract infection in a postmenopausal woman receiving adjuvant aromatase-inhibitor therapyMSRA

A 61-year-old woman requests advice about preventing recurrent urinary tract infection (UTI). She has had four culture-confirmed episodes of Escherichia coli lower UTI in the past 9 months, each causing dysuria and frequency without fever, loin pain or systemic illness. She is currently asymptomatic. She is postmenopausal and has vaginal dryness and dyspareunia. Increased fluid intake, avoiding delayed voiding and 3 months of regular vaginal moisturiser have not reduced either her genitourinary symptoms or UTI recurrence. There is no relationship between infections and sexual intercourse. Renal function and liver function are normal. Three years ago she was treated for oestrogen receptor-positive breast cancer and she remains on adjuvant anastrozole. She wishes to avoid long-term antibiotics if possible. What is the most appropriate next management step?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Discuss treatment options with her breast cancer specialist before considering vaginal oestrogen

Explanation lettering: B = shown as A · C = shown as B · A = shown as C · E = shown as D · D = shown as E

This patient has recurrent uncomplicated lower UTI and genitourinary symptoms of menopause despite behavioural measures and non-hormonal vaginal moisturiser. Vaginal oestrogen would ordinarily be an appropriate non-antibiotic preventive option for recurrent UTI in a postmenopausal woman. However, she is receiving an aromatase inhibitor as adjuvant treatment for oestrogen receptor-positive breast cancer. NICE advises working with a breast cancer specialist to identify treatment options when genitourinary symptoms persist despite non-hormonal treatment in this group. This is therefore the necessary next step before vaginal oestrogen is considered. A is attractive because methenamine hippurate is an antibiotic-sparing prophylactic option and alkalinising sachets reduce its efficacy. However, it is generally considered after behavioural measures and vaginal oestrogen or single-dose prophylaxis when these are appropriate; the immediate discriminator here is the need for specialist input regarding vaginal oestrogen during aromatase-inhibitor therapy. C omits that required specialist discussion. D is premature because daily antibiotic prophylaxis is considered after appropriate non-antibiotic and/or single-dose strategies have not helped. E is incorrect: systemic HRT should not be prescribed specifically to prevent recurrent UTI and is inappropriate in this context.

Reference: Urinary tract infection (recurrent): antimicrobial prescribing — Recommendations (Last updated 12 December 2024) — https://www.nice.org.uk/guidance/ng112/chapter/recommendations Menopause: identification and management — Recommendations (2024) — https://www.nice.org.uk/guidance/ng23/chapter/Recommendations Urinary tract infection (recurrent): antimicrobial prescribing — Recommendations (Last updated 12 December 2024) — https://www.nice.org.uk/guidance/ng112/chapter/recommendations